Figure S4 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

<p>Supplementary Figure S4. Impact on DNA replication, cell cycle, and apoptosis with PARP inhibitor treatment in BRCA2 wildtype and mutant cells – related to Figure 5. A) Graph showing quantification of % EdU-positive ‘S’ phase cells. DLD-1 BRCA2 mutant control or POLB knockout cells treated with 500 nM niraparib for 5 days followed by staining with Click-iT EdU flow cytometric assay. FACS data was analyzed by FloJo software. B) Histogram plots of cell cycle analysis using a propidium iodide assay in DLD-1 BRCA2 WT control or POLB knockout cells treated with 500 nM niraparib for 5 days (left). Quantification of each cell cycle phase (% cells) across all treatment conditions is shown in the graph (right). C) FACS plots showing apoptosis analysis with Annexin-V/PI staining in DLD-1 BRCA2 WT control or POLB knockout cells treated with 500 nM niraparib for 7 days (left). Quantification of % apoptotic cells (annexin V positive + annexin-V/PI positive) is shown for all the conditions tested (right).</p>

Authors

Publication Details

Published
2025-09-02
DOI
https://doi.org/10.1158/1535-7163.30028931
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Figure S4 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Brian Doyon, Madhavi Bandi, Tianshu Feng, William D. Mallender et al.
PARP inhibition in cancer therapy
article

Figure S4 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Brian Doyon, Madhavi Bandi, Tianshu Feng, William D. Mallender, Robert Tjin Tham Sjin, Jannik N. Andersen, Erik Wilker, Douglas A. Whittington, Alan Huang, Yi Yu, Xuewen Pan, Katherine Lazarides, Shangtao Liu, Hongxiang Zhang, Ashley H. Choi, Justin L. Engel, Binzhang Shen, Samuel R. Meier, Brian J. McMillan, Michele Meseonznik
article en

Abstract

<p>Supplementary Figure S4. Impact on DNA replication, cell cycle, and apoptosis with PARP inhibitor treatment in BRCA2 wildtype and mutant cells – related to Figure 5. A) Graph showing quantification of % EdU-positive ‘S’ phase cells. DLD-1 BRCA2 mutant control or POLB knockout cells treated with 500 nM niraparib for 5 days followed by staining with Click-iT EdU flow cytometric assay. FACS data was analyzed by FloJo software. B) Histogram plots of cell cycle analysis using a propidium iodide assay in DLD-1 BRCA2 WT control or POLB knockout cells treated with 500 nM niraparib for 5 days (left). Quantification of each cell cycle phase (% cells) across all treatment conditions is shown in the graph (right). C) FACS plots showing apoptosis analysis with Annexin-V/PI staining in DLD-1 BRCA2 WT control or POLB knockout cells treated with 500 nM niraparib for 7 days (left). Quantification of % apoptotic cells (annexin V positive + annexin-V/PI positive) is shown for all the conditions tested (right).</p>

Openalex Percentile: Top 68%
PARP inhibition in cancer therapy
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.